Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Aspire Biopharma Holdings, Inc. (ASBP) had Normalized Income after Taxes of $-15.94M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.94M |
|
-- |
|
-- |
|
$15.56M |
|
$-15.56M |
|
$-0.38M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
|
Normalized Income after Taxes |
$-15.94M |
$-15.56M |
|
$-15.56M |
|
37.89M |
|
37.89M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$1.97M |
|
-- |
|
-- |
|
$1.97M |
|
$8.87M |
|
-- |
|
$0.05M |
|
$8.92M |
|
$-6.95M |
|
$-6.95M |
|
$-6.95M |
|
48.90M |
|
| Cash Flow Statement Financials | |
$-1.75M |
|
-- |
|
$3.09M |
|
$0.00M |
|
$1.35M |
|
$1.34M |
|
$14.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.22 |
|
-- |
|
-- |
|
-- |
|
-0.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
229.28% |
|
229.28% |
|
-811.05% |
|
229.28% |
|
$-0.14 |
|
$-0.05 |
|
$-0.05 |
|